Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating because that oh-too-familiar routine of meetings, deadlines, and the like has returned with a vengeance.
You knew this would happen, yes? To cope, we are relying, as always, on cups of stimulation.
Our choice today is laced with chocolate raspberry. Feel free to join us.
Remember, no prescription is required. Meanwhile, here are some tidbits to help you along.
Best of luck accomplishing your goals today, and of course, do keep in touch. … Revolution Medicines’ experimental pancreatic cancer drug has been the star of the oncology field in recent weeks, with new data showing the medicine produced unprecedented outcomes for patients, but its next act — this time as a co-lead — was just revealed , STAT points out.
STAT News published a clinical update in Research Highlights on 08 Jun 2026.
The item focuses on STAT+: Pharmalittle: We’re reading about Lilly and Pfizer obesity drug data, Roche and J&J deals, and more.
Review the original article for the full source wording and details.